MTOR and prostate cancer: Several small molecule inhibitors of the PI3K pathway, including the pan-PI3K inhibitors ZSTK474 (Zenyaku Kogyo Co) and BKM120 (Novartis), and the dual PI3K/mTOR inhibitor BEZ235 (Novartis) have already entered early-phase clinical trials for treatment of solid malignancies, including prostate cancer [42]–[44].